Literature DB >> 17932808

Lentivirus as a potent and mechanistically distinct vector for genetic immunization.

Yukai He1, Louis D Falo.   

Abstract

T-cell-mediated immunity is critical for the prevention and control of a broad range of infectious diseases and human malignancies. Genetic immunization is a promising approach for the elicitation of T-cell immunity. Recombinant lentivectors are now being developed and evaluated as antigen delivery platforms for genetic immunization and immune engineering. Early results from studies utilizing lentivectors are promising. Third generation lentivectors have been engineered to improve biosafety and reduce antivector immune responses. The ability of third generation lentivectors to efficiently transduce non-dividing cells, including dendritic cells, suggests important advantages over other antigen delivery platforms. Studies suggest that immunization with lentivectors induces remarkably potent and durable primary and memory T-cell immunity. The combination of skin-targeted immunization and potentially unique mechanisms of immune induction likely contribute to the potent immunogenicity observed. Taken together, this accumulating evidence supports the ongoing development and clinical translation of lentivector-based genetic immunization strategies.

Entities:  

Mesh:

Year:  2007        PMID: 17932808      PMCID: PMC3065304     

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN: 1464-8431


  79 in total

1.  Intradermal influenza vaccination--can less be more?

Authors:  John R La Montagne; Anthony S Fauci
Journal:  N Engl J Med       Date:  2004-11-03       Impact factor: 91.245

Review 2.  Adenovirus vector-based vaccines for human immunodeficiency virus type 1.

Authors:  Dan H Barouch; Gary J Nabel
Journal:  Hum Gene Ther       Date:  2005-02       Impact factor: 5.695

Review 3.  Understanding presentation of viral antigens to CD8+ T cells in vivo: the key to rational vaccine design.

Authors:  Jonathan W Yewdell; S M Mansour Haeryfar
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

Review 4.  T cell vaccines for microbial infections.

Authors:  Harriet L Robinson; Rama Rao Amara
Journal:  Nat Med       Date:  2005-04       Impact factor: 53.440

5.  Upscaling of lentiviral vector production by tangential flow filtration.

Authors:  Martine Geraerts; Martine Michiels; Veerle Baekelandt; Zeger Debyser; Rik Gijsbers
Journal:  J Gene Med       Date:  2005-10       Impact factor: 4.565

Review 6.  Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors--design, biosafety, and production.

Authors:  P L Sinn; S L Sauter; P B McCray
Journal:  Gene Ther       Date:  2005-07       Impact factor: 5.250

7.  Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells.

Authors:  Adrien Kissenpfennig; Sandrine Henri; Bertrand Dubois; Corinne Laplace-Builhé; Pierre Perrin; Nikolaus Romani; Christoph H Tripp; Patrice Douillard; Lee Leserman; Dominique Kaiserlian; Sem Saeland; Jean Davoust; Bernard Malissen
Journal:  Immunity       Date:  2005-05       Impact factor: 31.745

8.  Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector.

Authors:  Yajin Ni; Susan Sun; Ibe Oparaocha; Laurent Humeau; Brian Davis; Reuben Cohen; Gwendolyn Binder; Yung-Nien Chang; Vladimir Slepushkin; Boro Dropulic
Journal:  J Gene Med       Date:  2005-06       Impact factor: 4.565

9.  CD8alpha+ dendritic cells selectively present MHC class I-restricted noncytolytic viral and intracellular bacterial antigens in vivo.

Authors:  Gabrielle T Belz; Ken Shortman; Michael J Bevan; William R Heath
Journal:  J Immunol       Date:  2005-07-01       Impact factor: 5.422

10.  Inducible ablation of mouse Langerhans cells diminishes but fails to abrogate contact hypersensitivity.

Authors:  Clare L Bennett; Erwin van Rijn; Steffen Jung; Kayo Inaba; Ralph M Steinman; Martien L Kapsenberg; Björn E Clausen
Journal:  J Cell Biol       Date:  2005-05-16       Impact factor: 10.539

View more
  16 in total

Review 1.  Immunization delivered by lentiviral vectors for cancer and infectious diseases.

Authors:  Biliang Hu; April Tai; Pin Wang
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

2.  A TLR4 agonist synergizes with dendritic cell-directed lentiviral vectors for inducing antigen-specific immune responses.

Authors:  Liang Xiao; Jocelyn Kim; Matthew Lim; Bingbing Dai; Lili Yang; Steven G Reed; David Baltimore; Pin Wang
Journal:  Vaccine       Date:  2012-02-05       Impact factor: 3.641

3.  Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma.

Authors:  Yuan Hong; Yibing Peng; Z Sheng Guo; Jose Guevara-Patino; Junfeng Pang; Lisa H Butterfield; Nahid F Mivechi; David H Munn; David L Bartlett; Yukai He
Journal:  Hepatology       Date:  2014-02-18       Impact factor: 17.425

4.  Transduction of human antigen-presenting cells with integrase-defective lentiviral vector enables functional expansion of primed antigen-specific CD8(+) T cells.

Authors:  Donatella R M Negri; Roberta Bona; Zuleika Michelini; Pasqualina Leone; Iole Macchia; Mary E Klotman; Mirella Salvatore; Andrea Cara
Journal:  Hum Gene Ther       Date:  2010-08       Impact factor: 5.695

5.  Redirecting lentiviral vectors pseudotyped with Sindbis virus-derived envelope proteins to DC-SIGN by modification of N-linked glycans of envelope proteins.

Authors:  Kouki Morizono; Amy Ku; Yiming Xie; Airi Harui; Sam K P Kung; Michael D Roth; Benhur Lee; Irvin S Y Chen
Journal:  J Virol       Date:  2010-05-19       Impact factor: 5.103

6.  Immunoglobulin Fc fragment tagging allows strong activation of endogenous CD4 T cells to reshape the tumor milieu and enhance the antitumor effect of lentivector immunization.

Authors:  Yuan Hong; Yibing Peng; Haiyan Xiao; Michael Mi; David Munn; Yukai He
Journal:  J Immunol       Date:  2012-04-13       Impact factor: 5.422

Review 7.  Engineering α-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma: review and future prospects.

Authors:  Yukai He; Yuan Hong; Gerald J Mizejewski
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

8.  Nonintegrating Lentiviral Vector-Based Vaccine Efficiently Induces Functional and Persistent CD8+ T Cell Responses in Mice.

Authors:  Donatella R M Negri; Zuleika Michelini; Silvia Baroncelli; Massimo Spada; Silvia Vendetti; Roberta Bona; Pasqualina Leone; Mary E Klotman; Andrea Cara
Journal:  J Biomed Biotechnol       Date:  2010-05-19

9.  Lentiviral vector-based prime/boost vaccination against AIDS: pilot study shows protection against Simian immunodeficiency virus SIVmac251 challenge in macaques.

Authors:  Anne-Sophie Beignon; Karine Mollier; Christelle Liard; Frédéric Coutant; Sandie Munier; Julie Rivière; Philippe Souque; Pierre Charneau
Journal:  J Virol       Date:  2009-08-12       Impact factor: 5.103

10.  Lentivector immunization stimulates potent CD8 T cell responses against melanoma self-antigen tyrosinase-related protein 1 and generates antitumor immunity in mice.

Authors:  Yanjun Liu; Yibing Peng; Michael Mi; Jose Guevara-Patino; David H Munn; Ning Fu; Yukai He
Journal:  J Immunol       Date:  2009-05-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.